Skip to content
Companies

Cadrenal Therapeutics

Drugs for heparin-induced thrombocytopenia and clotting

Raised to date

$16.8M

of $16.8M offered across 2 Form D filings

Investors
1
Last filed
Jul 15, 2026

About

Cadrenal Therapeutics is a late-stage biopharmaceutical company in Ponte Vedra, Florida developing treatments for life-threatening immune and thrombotic conditions. It is publicly traded on Nasdaq under the ticker CVKD and was founded in 2022 by Chairman and CEO Quang X. Pham. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia that is Phase 3-ready and carries FDA Orphan Drug and Fast Track designations. The pipeline also includes tecarfarin, an oral vitamin K antagonist anticoagulant, and frunexian, an intravenous Factor XIa inhibitor for acute hospital settings.

CAD-1005 targets the underlying immune mechanism of heparin-induced thrombocytopenia by selectively inhibiting 12-LOX, whereas existing HIT therapies only manage the resulting clotting complications; tecarfarin likewise uses a different metabolic pathway than warfarin, aimed at patients such as those with end-stage kidney disease or left ventricular assist devices where warfarin control is unreliable.

Funding

Apr 2026Jul
Now

$8.8M round, first sold Jun 2026: $8.8M sold

  • Security to be acquiredFiled Jul 15, 2026Form D
    $8.8M/ $8.8M
  • Security to be acquiredFiled Apr 6, 2026Form D
    $7.9M/ $7.9M

Product

CAD-1005

Clinical-stage therapeutic

A first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT), an immune-mediated thrombotic disorder. It is Phase 3-ready and holds FDA Orphan Drug and Fast Track designations.

  • First-in-class selective 12-LOX inhibitor
  • Targets the primary immune mechanism driving HIT
  • FDA Orphan Drug designation

Built for

Hospitals, cardiologists, nephrologists and hematologists treating patients who require chronic or acute anticoagulation — including end-stage kidney disease patients with atrial fibrillation, left ventricular assist device recipients, and patients who develop heparin-induced thrombocytopenia

People on file